Viking Therapeutics Inc: ECO 2026: Full Ph2a VENTURE-Oral Data Highlights Potential

Research evidence excerpt

Viking Therapeutics Inc: ECO 2026: Full Ph2a VENTURE-Oral Data Highlights Potential

Update

May 12, 2026 12:39 PM GMT

Morgan Stanley & Co. LLCMViking Therapeutics Inc | North America Michael E Ulz

Equity Analyst

ECO 2026: Full Ph2a VENTURE- Mike.Ulz@morganstanley.comRohit Bhasin +1 212 761-4650

Research Associate

Rohit.Bhasin@morganstanley.com +1 212 761-0534

Oral Data Highlights Potential Avraham Novick

Avi.Novick@morganstanley.com +1 212 761-2231

Key Takeaways

Viking Therapeutics Inc (VKTX.O, VKTX US)

Full 13-week oral trial data show early, dose-dependent weight loss throughout Biotechnology | United States of America

treatment period, with no evidence of plateauing. Stock Rating Overweight

Industry View Attractive

GI events occurred early and diminished over time, and a rapid 30-mg stepwise Price target $95.00

titration strategy appeared to support improving tolerability. Shr price, close (May 11, 2026) $31.72

Mkt cap, curr (mm) $3,666

Mgt. believes lower starting doses and longer titration windows may enhance 52-Week Range $43.15-22.96

tolerability profile.

Recall, oral VK2735 advancing directly into Ph3 from Ph2a following positive FDA

feedback, with the study expected to begin in 3Q26.

Overall, we believe the full oral dataset builds on VK2735's emerging profile, and

we look ahead to Ph1 maintenance data expected in 3Q26; Reiterate Overweight.

Lack of plateau with oral VK2735 suggests continued weight loss with longer

treatment. Viking presented additional data from its Ph2 VENTURE-Oral Dosing

trial evaluating the oral tablet formulation of VK2735 at the European Congress on

Obesity (ECO; Istanbul, Türkiye; press release; poster). Notably, VK2735 showed

early and dose dependent weight loss ( Exhibit 1 ), including stat sig reductions vs